← Leaderboards
Vargheese Mani Chennathukuzhi
University Of Kansas Medical Center
$5,256,841
Attributed
$8,152,765
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,152,765 · 7
By mechanism
R01$7,113,661 · 5
R61$779,754 · 1
U01$259,350 · 1
Top collaborators
- Warren B Nothnick5 shared
- Gunda I. Georg4 shared
- Aleksandar Rajkovic4 shared
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- Warren B Nothnick$6,618,470
- Joseph S Tash$4,247,537
- Sudhansu K Dey$18,014,179
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroWomanMouse ModelReproductiveTissuesGene ExpressionHysterectomyPathway InteractionsUterusRegulationPathogenesisMyometriumPharmaceutical PreparationsSignal PathwayKnockout MiceCellsCell ProliferationNeuronsMyometrialProteinsRestIn VivoSignal TransductionPlay
Grant awards (19)
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology$611,887
R01 · FY2025 · HD
REST-MED12 Pathways in the Regulation of Estrogen - Progesterone Sensitivity in Uterine Leiomyoma$529,820
R01 · FY2025 · HD · contact PI
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology$605,769
R01 · FY2024 · HD
REST-MED12 Pathways in the Regulation of Estrogen - Progesterone Sensitivity in Uterine Leiomyoma$547,140
R01 · FY2024 · HD · contact PI
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology$636,160
R01 · FY2023 · HD
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology$633,243
R01 · FY2022 · HD
REST/NRSF, miRNAs, and tissue remodeling in adenomyosis pathophysiology$642,705
R01 · FY2021 · HD
Allosteric CDK2 inhibitor Discovery and Development for Male Contraception$376,172
R61 · FY2020 · HD
Allosteric CDK2 inhibitor Discovery and Development for Male Contraception$403,582
R61 · FY2019 · HD
Small molecule GPR10 antagonists for the treatment of uterine fibroids$302,002
R01 · FY2019 · HD · contact PI
Cell-cycle regulatory kinases as targets for male contraceptive drug development$302,472
R01 · FY2018 · HD · contact PI
Small molecule GPR10 antagonists for the treatment of uterine fibroids$302,026
R01 · FY2018 · HD · contact PI
The role of REST in the pathogenesis of uterine fibroids$335,250
R01 · FY2017 · HD · contact PI
Cell-cycle regulatory kinases as targets for male contraceptive drug development$302,472
R01 · FY2017 · HD · contact PI
The role of REST in the pathogenesis of uterine fibroids$331,897
R01 · FY2016 · HD · contact PI
H2-Gamendazole analogues as reversible non-hormonal male contraceptive agents$259,350
U01 · FY2016 · HD · contact PI
The role of REST in the pathogenesis of uterine fibroids$326,867
R01 · FY2015 · HD · contact PI
The role of REST in the pathogenesis of uterine fibroids$343,130
R01 · FY2014 · HD · contact PI
The role of REST in the pathogenesis of uterine fibroids$360,821
R01 · FY2013 · HD · contact PI